Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 37-50

  Duan, Jianming ^a   Friedman, Jay ^a   Nottingham, Liesl ^a   Chen, Zhong ^a   Ara, Gulshan ^b   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b CURAGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; BORTEZOMIB; BUTYRIC ACID; CYCLIN D1; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; PROTEIN BCL XL; PROTEIN P21; PROTEIN P50; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; INHIBITOR OF APOPTOSIS PROTEIN; PROTEASOME; PROTEIN BCL X; PYRAZINE DERIVATIVE; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DNA BINDING; DRUG ACETYLATION; DRUG FATALITY; DRUG SENSITIVITY; GASTROINTESTINAL TOXICITY; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHARGY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SYSTEMIC DISEASE; TUMOR XENOGRAFT; WEIGHT REDUCTION; ACETYLATION; ANIMAL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROTEIN BINDING;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-X PROTEIN; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, NEOPLASM; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, SCID; NF-KAPPA B P50 SUBUNIT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PYRAZINES; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846850209     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0285     Document Type: Article

References (59)

1. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-6.
2. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001;8:1505-11.
3. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-68.
4. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14:1497-511.
5. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
6. Gillenwater A, Xu XC, Estrov Y, Sacks PG, Lotan D, Lotan R. Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int J Cancer 1998;75:217-24.
7. Saunders N, Dicker A, Popa C, Jones S, Dahler A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 1999; 59:399-404.
8. Coombes MM, Briggs KL, Bone JR, Clayman GL, El-Naggar AK, Dent SY. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. Oncogene 2003;22:8902-11.
9. Zhang Y, Jung M, Dritschilo A, Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004; 161:667-74.
10. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-κB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-29.
11. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-κb-α of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59:3468-74.
12. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-23.
13. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16: 225-60.
14. Sunwoo JB, Chen Z, Dong G, et al. Novel Proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7: 1419-28.
15. Duffey DC, Crowl-Bancroft CV, Chen Z, et al. Inhibition of transcription factor nuclear factor-κB by a mutant inhibitor-κBα attenuates resistance of human head and neck squamous cell carcinoma to TNF-α caspase-mediated cell death. Br J Cancer 2000;83:1367-74.
16. Kato T, Duffey DC, Ondrey FG, et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB. Head Neck 2000; 22:748-59.
17. Van Waes C, Sunwoo JB, DeGraff W, Mitchell JB. Radiosensitization and proteasome inhibition, In: Adams J, editor. Cancer drug discovery and development: proteasome inhibitors in cancer therapy. Totowa: Humana Press, Inc.; 2004. p. 123-30.
18. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001;293:1653-7.
19. Chen LF, Mu Y, Greene WC. Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 2002; 21:6539-48.
20. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002;13:1-13.
21. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003;983:84-100.
22. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD1 01. Mol Cancer Ther 2003;2:721-8.
23. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
24. Van Waes C, Chang A, Lebowitz PF, et al. Inhibition of NF-κB and target genes during combined therapy with proteasome inhibitor botezomib and re-irradiation in patients with recurrent head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-12.
25. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981;107:703-10.
26. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, P13K, and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99:538-48.
27. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-61.
28. Salgame P, Varadhachary AS, Primiano LL, Fincke JE, Muller S, Monestier M. An ELISA for detection of apoptosis. Nucleic Acids Res 1997;25:680-1.
29. Frankfurt OS, Krishan A. Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. J Immunol Methods 2001;253:133-44.
30. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 2006; 66:6722-31.
31. Zhang PL, Pellitteri PK, Law A, et al. Overexpression of phosphorylated nuclear factor-κB in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 2005; 18:924-32.
32. Mobley SR, Liu TJ, Hudson JM, Clayman GL. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy. Arch Otolaryngol Head Neck Surg 1998;124:88-92.
33. Basile JR, Eichten A, Zacny V, Munger K. NF-κB-mediated induction of p21 (Cip1/Waf1) by tumor necrosis factor α induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res 2003;1: 262-70.
34. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJP, Cheffetz S, Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999;59:4876-81.
35. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99.
36. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
37. Chen C, Edelstein LC, Gelinas C. The ReI/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20:2687-95.
38. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and BcI-xL. Mol Cancer Ther 2005;4:1096-104.
39. Mayo MW, Denlinger CE, Broad RM, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt Pathway. J Biol Chem 2003;278: 18980-9.
40. Denlinger CE, Rundall BK, Jones DR. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J Thorac Cardiovasc Surg 2005;130:1422-9.
41. Xueli F, Yingwang L, Jason JC. Down-regulation of p2l contributes to apoptosis induced by HPV E6 in human mammary epithelial cells. Apoptosis 2005;10:63.
42. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p2l in apoptosis. Mol Cancer Ther 2002;1:639-49.
43. Asada M, Yamada T, Ichijo H, et al. Apoptosis inhibitory activity of cytoplasmic p21 (Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18:1223-34.
44. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004;65:571-81.
45. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP. Predominant BcI-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005;65:2344-52.
46. Van Waes C. NF-κB in pathogenesis, prevention and therapy of cancer. Clin Cancer Res. In press 2007.
47. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
48. Chen CI, Kouroukis T, White D, et al. Bortezomib is active in Waldenstrom's macroglobulinemia - results of a National Cancer Institute of Canada phase II study in previously untreated WM. J Clin Oncol Suppl 2006;24:432s, 7543.
49. Lara PN, Gumerlock, PH, Crowley J, Gandara DR. Bortezomib and gemcitabine/carboplatin results in encouraging survival in advanced non-small cell lung cancer: results of a phase II Southwest oncology group trial (S0339). J Clin Oncol Suppl 2006;24:368s, 7017.
50. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005;23:5943-9.
51. Ma C, Mandrekar SJ, Alberts SR, et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chernother Pharmacol. in press 2007.
52. Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 2004;127:1078-86.
53. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004;128:740-8.
54. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomilb and histone deacetylase inhibitors. Clin Cancer Res 2004;10: 3839-52.
55. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-22.
56. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J Biol Chem 2001;276: 44641-6.
57. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005;25:5429-44.
58. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-κB activation. J Biol Chem 2006;281:5612-22.
59. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding. Mol Cancer Res 2005;3:100-9.